H.C. Wainwright reiterates Protalix BioTherapeutics Inc. [PLX] at Buy and assigns price target at $11

0
1138
ASTR Stock
ASTR Stock

H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX]‎ rating to the equivalent of ‎Buy but changed the price target ‎to $11, in a research note dated December 31, 2020. That figure ‎represents around a 212.5% ‎premium ‎from where the company’s shares closed on Wednesday.‎ Other ‎analysts also ‎revised their coverage, with H.C. Wainwright’s analysts reiterating the shares to “a Buy” ‎rating in a ‎research note to investors issued in early June. Meanwhile, Rodman & Renshaw had ‎maintained its ‎rating on PLX to the earlier “Buy” rating, in a research note produced for clients April 17, ‎‎2017. In ‎addition, there was a new coverage from Rodman & Renshaw on April 04, 2016. The research ‎firm ‎rated PLX “a Buy”.

Get the hottest stocks to trade every ‎day before the ‎market opens 100% free. Click here now. ‎‎

Is Protalix ‎BioTherapeutics Inc. [AMEX:PLX] a Good Buy Right Now?

It should be noted that ‎PLX technical ‎indicators for short, intermediate as well as long term progress have placed an overall ‎average of 24% ‎as Sell. The average signal changed from 8% Sell in the last week and compares with ‎‎32% Buy in the ‎past month. Data from Protalix BioTherapeutics Inc.’s Trend Spotter indicated that the ‎signals were ‎Weakening. The stock current average is 0.19 million shares in the past 20 days and the ‎short term ‎average signal indicates a Hold. In the last 50 days, the average trading volume was 0.14 ‎million shares ‎while the medium term average advocated for 50% Sell. The average long-term signal ‎stands at Hold ‎and the 100-day average volume stands at 0.14 million shares.‎‎


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


PLX Price Performance

On ‎Wall Street, Protalix BioTherapeutics Inc. [AMEX:PLX] finished ‎Wednesday’s session up 1.15% at $3.52. ‎The stock went up to $3.76 at the same session while its ‎lowest single day price was $3.45. In the last ‎five days, it saw a rise of about 1.44%, Protalix ‎BioTherapeutics Inc. shares gained by almost 7.32% ‎since the beginning of the year. However, the ‎share price has dropped to as low as -27.65% below its ‎one year high. On 04/29/20, the company ‎shares recorded $4.86, the highest single-day price it has got ‎to in the last 52-weeks and a 52-week low ‎was seen on 03/16/20, the same year at $2.04. The ‎company’s shares have inclined by 7.32% in the ‎past year. The 50-day SMA achieved is $3.54 while the ‎‎200-day SMA is $3.48. Volume gained to 0.57 ‎million from 0.15 million in the previous session.‎‎

PLX ‎Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived ‎around 3.39 level, and in case of violation of this particular level, it will cause more drop to ‎‎3.27 level. ‎On the upper level, 3.89 is still the key resistance. The stock may increase to the subsequent ‎resistance ‎at 3.70. The Relative Strength Index (RSI) pinned on the 14-day chart is 48.35, implying a ‎neutral ‎technical stance while the MACD stands at -0.04, meaning price will decrease in the next ‎trading ‎period. Percent R indicator moved to 64.00%, implying low price movement. Stochastic %K at ‎‎36.00% ‎suggest selling the stock.‎‎

What is the short interest in Protalix BioTherapeutics Inc.?

Short ‎interest in the Protalix ‎BioTherapeutics Inc. stock has plunged, decreasing by -0.15 million shares to ‎total 0.28 million shares ‎on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.13 ‎million, data from Yahoo ‎Finance shows. The increase of 53.66% suggests the stock saw some ‎increased bearish sentiment. The ‎stock’s days to cover (short ratio) moved to while the shorted shares ‎account for just 0.86% of the ‎overall float for the stock.‎‎

Protalix BioTherapeutics Inc.’s Biggest ‎Shareholders: Who Owns Protalix BioTherapeutics Inc. ‎‎[PLX]?

Filings by Highbridge Capital ‎Management LLC showed that the firm now holds a total of ‎‎2,414,487 shares or roughly 7.24% of the ‎outstanding PLX shares. This means their shares have ‎reduced by 0 from the 2,414,487 the investor ‎reportedly held in its prior 13-F filing. With the conclusion ‎of the sale, Renaissance Technologies LLC ‎updated stake is worth $1,760,299. Details in the latest 13F ‎filings reveal that Psagot Mutual Funds Ltd. ‎disposed off their 0.00% stake valued at $1,688,215 while ‎Medical Strategy GmbH cut theirs at ‎‎$1,484,824. ‎‎

PLX Earnings Forecast For The Current Quarter

Protalix BioTherapeutics Inc. ‎‎[PLX] is ‎expected to report weak earnings results for the quarter ending on Dec 2020. Consensus ‎estimates ‎give the company expected revenues of $11.98M and an earnings per share of -$0.08 for ‎Dec 2020. ‎Looking further ahead, the company is expected to report revenue of $16.1M at an EPS of -‎‎$0.02 for ‎Mar 2021. The estimates represent downside of 9.40% and 102.60% in the company’s ‎revenue and ‎earnings per share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

PLX Earnings Estimates For The ‎Current ‎Year

For the financial year, Protalix BioTherapeutics Inc. [AMEX:PLX] is expected to bring ‎in ‎revenue of $55.31M. The returns are nearly $0.62 million higher than the company’s actual ‎revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -0.39, higher ‎than that ‎of FY19 by $0.84. Estimates put this year’s earnings growth at 68.30%, 102.60% for the next, ‎and at an ‎annual 25.00% over the next 5-year period. As for sales, forecasts are for an increase of ‎‎1.10% in the ‎current fiscal year and a further 9.40% over the following year.‎

LEAVE A REPLY

Please enter your comment!
Please enter your name here